Patent: 10,125,195
✉ Email this page to a colleague
Summary for Patent: 10,125,195
Title: | Stable anti-IFNAR1 formulation |
Abstract: | The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-INFAR1 antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interferon alpha 1 (INFAR1); about 20 mM to about 80 mM of a lysine or a salt thereof; about 0.02% to about 0.06% of a surfactant; an uncharged excipient; and a formulation buffer. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation. |
Inventor(s): | Depaz Roberto, DeJesus Natalie, Bee Jared |
Assignee: | AstraZeneca AB |
Application Number: | US15240224 |
Patent Claims: | see list of patent claims |
Details for Patent 10,125,195
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Astrazeneca Ab | SAPHNELO | anifrolumab-fnia | Injection | 761123 | July 30, 2021 | ⤷ Subscribe | 2036-08-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |